Clinical trial design for new cancer therapies has historically been focused on a tumor’s tissue of origin, but a Memorial Sloan Kettering paper supports a new approach: one based on the genomic signature of a tumor rather than its tissue of origin.
The US Preventive Services Task Force has recommended that breast cancer primary prevention drugs be offered to higher-risk women at low risk of side effects. Memorial Sloan Kettering’s Chief of Breast Cancer Medicine, Clifford Hudis, is available to discuss
The largest radiation oncology event in the world, the ASTRO annual meeting, will take place in Atlanta, September 22-25. Memorial Sloan Kettering radiation oncologists are available to comment on breaking news out of the meeting.
Women with breast cancer and relatively favorable prognoses often face treatment choices that balance small gains in outcome with possible negative effects. Medical oncologist Larry Norton and breast surgeon Monica Morrow are available to weigh in on this topic.
The US Preventive Services Task Force recommends screening people who are at high risk for lung cancer with annual low-dose CT scans. Thoracic surgeon Nabil Rizk and pulmonologist and epidemiologist Peter Bach are available to discuss the importance of these recommendations.